Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer

Table 3 Doses delayed and dose adjustment (decrease) in patients with rash/acneiform rash according to the toxicity grades (Primary analysis set, n = 229)

	Day 15 (n = 214)	Month 1 (n = 208)	Month 2 (n = 186)	Month 3 (n = 153)	Month 4 (n = 122)	Month 5 (n = 93)	Month 6 (n = 87)
Rash/acneiform rash, grade 1-2, n	101	115	99	82	51	39	33
Doses delayed, n (%)	2 (2.0)	4 (3.5)	13 (13.1)	21 (25.9)	4 (7.8)	4 (10.3)	9 (27.3)
MD	0	0	0	1	0	0	0
Dose adjustment, n (%)	0	7 (6.3)	3 (3.3)	13 (16.9)	12 (25.5)	8 (20.5)	6 (18.2)
MD	1	3	8	5	4	0	3
Rash/acneiform rash, grade 3-4, n	10	7	8	2	4	1	1
Doses delayed, n (%)	1 (10.0)	1 (14.3)	4 (50.0)	2 (100)	1 (25.0)	0	0
MD	0	0	0	0	0	0	0
Dose adjustment, n (%)	2 (25.0)	0	2 (33.3)	2 (100)	1 (25.0)	0	0
MD	2	2	2	0	0	0	1

MD: Missing data.